travellinglight/iStock via Getty Images
Annovis Bio (NYSE:ANVS) announced Tuesday that the U.S. Food and Drug Administration (FDA) accepted an updated protocol for a pivotal Phase 3 trial for its Alzheimer’s candidate, buntanetap.
The study based on Phase 2/3 data for the oral small molecule